MacroGenics, Inc. Share Price Today: Live Updates & Key Insights

MacroGenics, Inc. share price today is $2.95, up -1.38%. The stock opened at $2.88 against the previous close of $2.9, with an intraday high of $2.9182 and low of $2.81.

MacroGenics, Inc. Share Price Chart

MacroGenics, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

MacroGenics, Inc. Share Price Performance

$2.95 -0.0138(-1.38%) MGNX at 23 Mar 2026 02:16 PM Biotechnology
Lowest Today 2.81
Highest Today 2.9182
Today’s Open 2.88
Prev. Close 2.9
52 Week High 3.54
52 Week Low 0.99
Day’s Range: Low 2.81 High 2.9182
52-Week Range: Low 0.99 High 3.54
1 day return -
1 Week return -7.74
1 month return +62.5
3 month return +78.75
6 month return +64.36
1 year return +45.91
3 year return -57.44
5 year return -91.25
10 year return -

MacroGenics, Inc. Institutional Holdings

BB Biotech AG Ord 15.67

Armistice Capital, LLC 9.99

Vanguard Group Inc 6.68

Renaissance Technologies Corp 4.59

Acadian Asset Management LLC 3.98

Millennium Management LLC 3.12

Vanguard Total Stock Mkt Idx Inv 3.04

Wasatch Advisors LP 2.82

Wasatch Ultra Growth 2.62

BlackRock Inc 2.43

JPMorgan Chase & Co 2.39

Marshall Wace Asset Management Ltd 2.03

Jane Street Group LLC 1.98

Two Sigma Advisers, LLC 1.89

Citadel Advisors Llc 1.63

Two Sigma Investments LLC 1.58

Morgan Stanley - Brokerage Accounts 1.56

Jacobs Levy Equity Management, Inc. 1.42

Connor Clark & Lunn Inv Mgmt Ltd 1.29

D. E. Shaw & Co LP 1.20

Geode Capital Management, LLC 1.03

Vanguard Institutional Extnd Mkt Idx Tr 1.03

GSA Capital Partners LLP 0.81

Affinity Asset Advisors, LLC 0.76

Vanguard Strategic Small-Cap Equity Inv 0.69

Vanguard VIF Small Co Gr 0.69

Nomura Healthcare Fund Class I 0.66

PPF Helix Biotechnology I USD 0.61

PSM Macro Strategy 0.54

PSM Value Strategy UI 0.47

Fidelity Extended Market Index 0.30

Mackenzie GQE US Small Cap F8 0.30

Vanguard Explorer Inv 0.28

iShares Micro-Cap ETF 0.25

Vanguard Health Care ETF 0.25

Blackrock Extended Mkt Fund CF 0.23

Extended Equity Market Fund K 0.20

Invesco RAFI US 1500 Small-Mid ETF 0.18

Fidelity Total Market Index 0.18

Wasatch Long Short Alpha Composite 0.15

MacroGenics, Inc. Market Status

Strong Buy: 2

Buy: 1

Hold: 6

Sell: 0

Strong Sell: 0

MacroGenics, Inc. Fundamentals

Market Cap 181.77 M

PB Ratio 3.2698

PE Ratio 0.0

Enterprise Value 28.62 M

Total Assets 256.85 M

Volume 644158

MacroGenics, Inc. Company Financials

Annual Revenue FY23:58749000 58.7M, FY22:151941000 151.9M, FY21:75643000 75.6M, FY20:97764000 97.8M, FY19:62024000 62.0M

Annual Profit FY23:40882000 40.9M, FY22:144557000 144.6M, FY21:72992000 73.0M, FY20:97764000 97.8M, FY19:62024000 62.0M

Annual Net worth FY23:-9058000 -9.1M, FY22:-120021000 -120.0M, FY21:-190857000 -190.9M, FY20:-117782000 -117.8M, FY19:-151811000 -151.8M

Quarterly Revenue Q3/2025:72839000 72.8M, Q2/2025:22241000 22.2M, Q1/2025:13192000 13.2M, Q3/2024:110708000 110.7M, Q2/2024:10797000 10.8M

Quarterly Profit Q3/2025:59461000 59.5M, Q2/2025:13335000 13.3M, Q1/2025:7792000 7.8M, Q3/2024:108838000 108.8M, Q2/2024:6163000 6.2M

Quarterly Net worth Q3/2025:16822000 16.8M, Q2/2025:-36251000 -36.3M, Q1/2025:-41036000 -41.0M, Q3/2024:56309000 56.3M, Q2/2024:-55664000 -55.7M

About MacroGenics, Inc. & investment objective

Company Information MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Organisation Biotechnology

Employees 293

Industry Biotechnology

CEO Mr. Eric Blasius Risser

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

MacroGenics, Inc. FAQs

What is the share price of MacroGenics, Inc. today?

The current share price of MacroGenics, Inc. is $2.95.

Can I buy MacroGenics, Inc. shares in India?

Yes, Indian investors can buy MacroGenics, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy MacroGenics, Inc. shares in India?

You can easily invest in MacroGenics, Inc. shares from India by:

Can I buy fractional shares of MacroGenics, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of MacroGenics, Inc.?

MacroGenics, Inc. has a market cap of $181.77 M.

In which sector does MacroGenics, Inc. belong?

MacroGenics, Inc. operates in the Biotechnology sector.

What documents are required to invest in MacroGenics, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of MacroGenics, Inc.?

The PE ratio of MacroGenics, Inc. is N/A and the PB ratio is 3.27.